Skip to search formSkip to main contentSkip to account menu

S 9788

Known as: S-9788, S9788 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

Antineoplastic AgentsPiperidinesTriazines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1999
1999
Comparative 99mTc-sestamibi and 3H-daunomycin uptake in human carcinoma cells: relation to the MDR phenotype and effects of reversing agents.
UNLABELLED Because 99mTc-sestamibi (MIBI) appears to be a potent candidate for multidrug resistance (MDR) evaluation in tumors… 
1998
1998
Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors
Purpose: The objectives of this phase I study were to evaluate the toxic effects and the maximum tolerated dose (MTD) of S9788, a… 
Review
1997
Review
1997
Anthracycline subcellular distribution in human leukemic cells by microspectrofluorometry: factors contributing to drug-induced cell death and reversal of multidrug resistance
There is a large discrepancy between the changes in drug accumulation and the changes in drug cytotoxicity that accompany… 
1997
1997
Evidence for reversal of multidrug resistance by quinine in LR73 cells without alteration of nuclear pirarubicin uptake and down‐regulation of mdr1 gene expression
Confocal laser microspectrofluorometry was used to investigate restoration of nuclear pirarubicin (THP‐DOX) accumulation and… 
1996
1996
Effects of modulators of multidrug resistance on the expression of the MDR1 gene in human KB cells in culture
The effect of four modulators of multidrug resistance (MDR) on the expression of the MDR1 gene was studied in two resistant… 
1995
1995
Cyclosporin A, verapamil and S9788 reverse doxorubicin resistance in a human medullary thyroid carcinoma cell line
Multidrug resistance was investigated in TT cells, a human medullary thyroid carcinoma (MTC) cell line and in normal thyrocytes… 
1994
1994
Comparative evaluation of S9788, verapamil, and cyclosporine A in K562 human leukemia cell lines and in P-glycoprotein-expressing samples from patients with hematologic malignancies.
The activity of S9788, recently synthetized as a modulator of multidrug resistance (MDR), was compared with verapamil and… 
1994
1994
Effect of S9788, cyclosporin A and verapamil on intracellular distribution of THP-doxorubicin in multidrug-resistant K562 tumor cells, as studied by laser confocal microspectrofluorometry.
S9788 modulating resistance effect has been investigated on the activity of THP-DOX against multidrug-resistant K562R cells and… 
1993
1993
Evaluation of S9788 as a potential modulator of drug resistance against human tumour sublines expressing differing resistance mechanisms In Vitro
Significant activity has been identified using S9788, a triazineaminopiperidine derivative, as a new modulator of multidrug… 
1993
1993
Effect of duration of exposure to S9788, cyclosporin A or verapamil on sensitivity of multidrug resistant cells to vincristine or doxorubicin.
In order to explain the high potency of S9788, a new multidrug resistance modifier currently in clinical development, we… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)